José Castillo Selected Research

Anticoagulants

1/2022	A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype.
1/2019	Influence of Sex on Stroke Prognosis: A Demographic, Clinical, and Molecular Analysis.
1/2003	Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José Castillo Research Topics

Disease

84	Stroke (Strokes) 03/2024 - 04/2002
68	Ischemic Stroke 03/2024 - 08/2002
28	Brain Ischemia (Cerebral Ischemia) 01/2022 - 01/2003
27	Inflammation (Inflammations) 01/2023 - 10/2005
26	Infarction (Infarctions) 01/2019 - 10/2002
16	Ischemia 10/2018 - 01/2003
9	Brain Injuries (Brain Injury) 01/2018 - 10/2002
7	Hematoma 07/2021 - 01/2007
7	Cerebral Hemorrhage 12/2020 - 07/2003
7	Migraine Disorders (Migraine) 03/2020 - 05/2007
6	Necrosis 02/2024 - 10/2002
6	Periodontitis 11/2023 - 01/2019
6	Embolic Stroke 01/2022 - 08/2012
6	Cerebral Infarction 01/2021 - 01/2003
5	Leukoaraiosis 02/2024 - 10/2010
5	Lacunar Stroke 01/2019 - 05/2002
5	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2018 - 10/2002
4	Hypothermia 01/2020 - 09/2005
4	Atherosclerosis 09/2016 - 06/2012
4	Edema (Dropsy) 01/2013 - 01/2007
4	Brain Edema (Cerebral Edema) 12/2012 - 09/2005
4	Hypertension (High Blood Pressure) 07/2009 - 05/2002
3	Alzheimer Disease (Alzheimer's Disease) 11/2023 - 03/2019
3	Hyperthermia 07/2020 - 03/2003
3	Hemorrhage 06/2017 - 07/2004
2	Obesity 02/2022 - 01/2021
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 03/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2020
2	Atrial Fibrillation 01/2019 - 07/2013
2	Iron Overload 01/2018 - 01/2007
2	Transient Ischemic Attack 01/2017 - 08/2013
2	Asphyxia (Suffocation) 01/2017 - 01/2016
2	Hyperglycemia 10/2010 - 03/2003
2	Headache (Headaches) 05/2007 - 10/2005

Drug/Important Bio-Agent (IBA)

31	Biomarkers (Surrogate Marker)IBA 02/2024 - 10/2005
25	Glutamic Acid (Glutamate)FDA Link 06/2022 - 10/2002
21	Interleukin-6 (Interleukin 6)IBA 06/2022 - 04/2002
15	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2024 - 01/2003
14	Neuroprotective AgentsIBA 01/2022 - 12/2002
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 04/2002
9	Proteins (Proteins, Gene)FDA Link 11/2023 - 07/2003
9	EnzymesIBA 01/2022 - 01/2003
9	Oxaloacetic Acid (Oxalacetic Acid)IBA 01/2017 - 06/2011
8	Cytidine Diphosphate Choline (Citicoline)IBA 08/2016 - 12/2002
7	Transaminases (Aminotransferases)IBA 01/2017 - 06/2011
6	Fibronectins (Fibronectin)IBA 11/2020 - 07/2004
6	Matrix Metalloproteinase 9 (Gelatinase B)IBA 07/2020 - 01/2003
6	IronIBA 01/2020 - 10/2002
6	erucylphosphocholineIBA 04/2017 - 10/2007
5	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2022 - 01/2009
5	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 03/2005
5	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 06/2013 - 06/2007
5	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2012 - 01/2009
4	C-Reactive ProteinIBA 06/2022 - 06/2012
4	InterleukinsIBA 02/2022 - 03/2003
4	Therapeutic UsesIBA 01/2022 - 02/2011
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 12/2009
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2012 - 01/2006
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2012 - 08/2003
4	CytokinesIBA 06/2008 - 05/2002
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 03/2024 - 02/2011
3	Endothelin-1 (Endothelin 1)IBA 01/2023 - 07/2008
3	AnticoagulantsIBA 01/2022 - 01/2003
3	Matrix Metalloproteinases (MMPs)IBA 07/2021 - 01/2008
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 06/2007
3	Peptides (Polypeptides)IBA 01/2020 - 12/2017
3	Oxygen (Dioxygen)IBA 10/2018 - 03/2005
3	Interleukin-10 (Interleukin 10)IBA 01/2018 - 03/2003
3	NeuroserpinIBA 05/2011 - 02/2011
3	Antihypertensive Agents (Antihypertensives)IBA 07/2009 - 02/2004
2	Contrast MediaIBA 10/2022 - 03/2019
2	Fibrinogen (Factor I)FDA Link 06/2022 - 01/2005
2	LeptinIBA 02/2022 - 01/2018
2	AdiponectinIBA 02/2022 - 01/2018
2	CeramidesIBA 01/2022 - 01/2021
2	SphingolipidsIBA 01/2022 - 01/2021
2	LipidsIBA 01/2021 - 09/2016
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2020 - 01/2018
2	PTX3 proteinIBA 03/2020 - 01/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 12/2009
2	Amyloid beta-PeptidesIBA 01/2020 - 03/2019
2	Indicators and Reagents (Reagents)IBA 01/2019 - 03/2015
2	pro-brain natriuretic peptide (1-76)IBA 01/2019 - 05/2015
2	Collagenases (Collagenase)FDA Link 10/2018 - 07/2015
2	Natriuretic PeptidesIBA 12/2017 - 05/2015
2	HaptoglobinsIBA 06/2012 - 08/2009
2	Excitatory Amino Acid AntagonistsIBA 02/2012 - 03/2006
2	Transcription Factors (Transcription Factor)IBA 03/2010 - 01/2008
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 06/2008 - 08/2002
2	Ferritins (Ferritin)IBA 01/2008 - 01/2007
2	ProstaglandinsIBA 02/2006 - 06/2005
2	Nitric Oxide Synthase (NO Synthase)IBA 03/2005 - 08/2003
2	Adenosine Triphosphate (ATP)IBA 03/2005 - 03/2005

Therapy/Procedure

33	Therapeutics 03/2024 - 09/2005
5	Thrombolytic Therapy 01/2021 - 01/2003
4	Secondary Prevention 01/2020 - 05/2012
3	Aftercare (After-Treatment) 06/2007 - 07/2004
2	Low-Level Light Therapy (LLLT) 09/2020 - 01/2019
2	Injections 04/2020 - 01/2012
2	Immunomodulation 01/2009 - 01/2008